FDA Adds Heart Disease Risk, Diabetes Warning to Prostate Cancer Drugs
Federal drug regulators are calling for new heart disease and diabetes warnings to be added to a class of prostate cancer drugs that includes Eligard, Lupron, Synarel, Trelstar, Vantas, Viadur,…